Press Releases

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

November 02, 2011
Utrecht (the Netherlands) - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Und...
Read more

ISA Pharmaceuticals strengthens its Supervisory Board with the appointment of Professor Jan van de Winkel

October 17, 2011
Leiden, The Netherlands, October 17th, 2011 - ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van...
Read more

FDA grants ISA Pharmaceuticals Orphan Drug Designation for the treatment of Vulvar Intraepithelial Neoplasia with its lead product ISA-HPV-SLP®

October 05, 2011
Leiden, The Netherlands, October 5th , 2011 ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designati...
Read more

Merus launches MeMo™, a transgenic mouse for improved therapeutic human monoclonal antibodies

September 27, 2011
Utrecht, The Netherlands, September 27, 2011 - Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibod...
Read more

Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics

September 12, 2011
Collaboration to investigate potential of AtuPLEX™ in the development of novel microRNA therapeutics targeting cancer London, UK & Nijmegen/Utrecht, Netherlands, September 12, 2011 - Silence Therapeutics pl...
Read more

SomantiX announces establishment of Scientific Advisory Board

July 07, 2011
Amsterdam (the Netherlands) - July 7, 2011 - SomantiX B.V., a biotech company focused on the development of new angiogenesis inhibitors, announces the establishment of its Scientific Advisory Board. Tumor...
Read more

ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology

July 04, 2011
Amsterdam, The Netherlands - July 4th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual prop...
Read more

Aglaia announces sale of portfolio company Syntarga

June 23, 2011
Bilthoven, June 23, 2011 - Aglaia Oncology Fund is pleased to announce the acquisition of its portfolio company Syntarga B.V. b...
Read more
Aglaia announces sale of portfolio company Syntarga

ISA Pharmaceuticals closes a License Agreement with Transgene aimed at the development of novel vaccines for TB

May 26, 2011
Leiden, The Netherlands, May 26th, 2011 - ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Tra...
Read more

Merus and ChromaCon receive a € 1.8 million project grant for the discovery and development of bispecific antibodies for therapy of advanced breast cancer

May 16, 2011
Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 - Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bis...
Read more

ISA Pharmaceuticals and Prosensa receive Mibiton funding for peptide manufacturing facility

May 12, 2011
Leiden, The Netherlands, April 26th , 2011 - ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that Mibiton supports IS...
Read more

InteRNA Technologies Strengthens its R&D Team

April 29, 2011
Nijmegen/Utrecht, The Netherlands, April 29th, 2011 - InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce...
Read more

ISA Pharmaceuticals embarks on EUR 4 million Cancer Vaccine development track awarded by CTMM

March 22, 2011
ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded...
Read more

Merus receives € 0.75 million grant for the discovery and development of Oligoclonics™ antibody therapy for colon cancer.

January 05, 2011
Utrecht, The Netherlands, January 5th 2010 ‐ Merus announced today that it has received a € 0.75 million grant for the discovery and development of an antibody combination therapy for colon cancer using its...
Read more

Press release Innovation Credit_InteRNA

November 16, 2010
Date: 16 November, 2010 InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company developing path...
Read more

KWF Kankerbestrijding reikt KWO-prijzen 2010 uit.

October 12, 2010
6 mln euro voor tumorimmunologie en langetermijngevolgen kankerbehandeling 7 december 2010 - Prof.dr.ir. Floor van Leeuwen (NKI-AVL), prof.dr. Kees Melief (LUMC) en prof.dr Carl Figdor (UMC St. Radboud) ont...
Read more

Dr. Wolfgang Berthold joins Supervisory Board Merus

September 20, 2010
Utrecht, the Netherlands (September 20, 2010) - Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. "We are delighted to appoint Wolf Ber...
Read more

InteRNA Technologies announces establishment of Scientific Advisory Board

July 08, 2010
Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of it...
Read more

Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP® for phase III clinical trials

June 02, 2010
Bubendorf, Switzerland and Leiden, Netherlands, Bachem (SIX: BANB) and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of...
Read more

Merus Announces Publication of the Generation of Single, Clonal Cell lines

June 02, 2010
Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the 'Early View' section of the journal Biotechnology and Bioengineering that demonstrate for the first time...
Read more

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds